JP2018516917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516917A5 JP2018516917A5 JP2017561810A JP2017561810A JP2018516917A5 JP 2018516917 A5 JP2018516917 A5 JP 2018516917A5 JP 2017561810 A JP2017561810 A JP 2017561810A JP 2017561810 A JP2017561810 A JP 2017561810A JP 2018516917 A5 JP2018516917 A5 JP 2018516917A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims 2
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 claims 2
- 102100033144 Cyclin-dependent kinase 18 Human genes 0.000 claims 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 2
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims 2
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 claims 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 2
- 108010039798 PCTAIRE-3 protein kinase Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940127113 compound 57 Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2803/CHE/2015 | 2015-06-04 | ||
| IN2803CH2015 | 2015-06-04 | ||
| IN6214/CHE/2015 | 2015-11-18 | ||
| IN6214CH2015 | 2015-11-18 | ||
| PCT/IB2016/053267 WO2016193939A1 (en) | 2015-06-04 | 2016-06-03 | Substituted heterocyclyl derivatives as cdk inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020131775A Division JP7033764B2 (ja) | 2015-06-04 | 2020-08-03 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516917A JP2018516917A (ja) | 2018-06-28 |
| JP2018516917A5 true JP2018516917A5 (enExample) | 2019-07-04 |
| JP6750806B2 JP6750806B2 (ja) | 2020-09-02 |
Family
ID=57440798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561810A Active JP6750806B2 (ja) | 2015-06-04 | 2016-06-03 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
| JP2020131775A Expired - Fee Related JP7033764B2 (ja) | 2015-06-04 | 2020-08-03 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
| JP2022024039A Active JP7482918B2 (ja) | 2015-06-04 | 2022-02-18 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020131775A Expired - Fee Related JP7033764B2 (ja) | 2015-06-04 | 2020-08-03 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
| JP2022024039A Active JP7482918B2 (ja) | 2015-06-04 | 2022-02-18 | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10689347B2 (enExample) |
| EP (2) | EP3302448B1 (enExample) |
| JP (3) | JP6750806B2 (enExample) |
| KR (1) | KR102691467B1 (enExample) |
| CN (2) | CN113773257A (enExample) |
| AU (3) | AU2016272908B2 (enExample) |
| CA (1) | CA2987552A1 (enExample) |
| CU (1) | CU24496B1 (enExample) |
| DK (1) | DK3302448T3 (enExample) |
| EA (1) | EA037236B1 (enExample) |
| FI (1) | FI3302448T3 (enExample) |
| HR (1) | HRP20240101T1 (enExample) |
| IL (2) | IL255960B (enExample) |
| LT (1) | LT3302448T (enExample) |
| MX (2) | MX375639B (enExample) |
| MY (2) | MY198769A (enExample) |
| PH (1) | PH12017502179B1 (enExample) |
| SI (1) | SI3302448T1 (enExample) |
| WO (1) | WO2016193939A1 (enExample) |
| ZA (1) | ZA201800022B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6789962B2 (ja) * | 2015-03-09 | 2020-11-25 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体 |
| EP3302448B1 (en) | 2015-06-04 | 2023-10-25 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
| GB201617548D0 (en) | 2016-10-17 | 2016-11-30 | Linnane Pharma Ab | Novel biological factor |
| TWI703149B (zh) | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| KR20200104873A (ko) | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
| US11472774B2 (en) | 2018-02-01 | 2022-10-18 | The University Of Sydney | Anti-cancer compounds |
| SMT202400346T1 (it) * | 2018-03-29 | 2024-11-15 | Takeda Pharmaceuticals Co | Composto eterociclico |
| CA3095987A1 (en) * | 2018-04-04 | 2019-10-10 | Aurigene Discovery Technologies Limited | Substituted pyrazole derivatives as selective cdk12/13 inhibitors |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN110590747B (zh) * | 2018-06-12 | 2022-03-22 | 隆泰申医药科技(南京)有限公司 | 一种化合物、其制备方法、药物组合物和应用 |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| JP2021529740A (ja) | 2018-06-29 | 2021-11-04 | キネート バイオファーマ インク． | サイクリン依存性キナーゼの阻害剤 |
| UA125427C2 (uk) * | 2018-09-17 | 2022-03-02 | Юнґдзин Фарм. Ко., Лтд. | Похідні тіазолу і їх фармацевтично прийнятні солі |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| WO2020202001A1 (en) | 2019-04-01 | 2020-10-08 | Aurigene Discovery Technologies Limited | Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors |
| CN110845474B (zh) * | 2019-11-07 | 2021-01-12 | 四川大学 | 一种靶向i型prmt的化合物及其制备方法和应用 |
| CN115485274A (zh) * | 2020-03-13 | 2022-12-16 | 永进药品株式会社 | 包含噻唑衍生物或其药学上可接受的盐的用于预防或治疗癌症的药物组合物 |
| WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| TWI783480B (zh) | 2020-05-27 | 2022-11-11 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
| MX2023007218A (es) * | 2020-12-18 | 2023-07-27 | Aurigene Oncology Ltd | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). |
| CA3215788A1 (en) * | 2021-04-27 | 2022-11-03 | Aurigene Oncology Limited | Process for preparing a cdk inhibitor |
| WO2022249141A2 (en) * | 2021-05-28 | 2022-12-01 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent |
| MX2023015245A (es) * | 2021-06-16 | 2024-01-19 | Blueprint Medicines Corp | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. |
| UY39832A (es) | 2021-06-28 | 2023-01-31 | Blueprint Medicines Corp | Inhibidores de cdk2 |
| TW202327583A (zh) * | 2021-12-06 | 2023-07-16 | 美商艾克塞里克斯公司 | 使用ｃｄｋ７抑制劑治療癌症之方法 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN118973401B (zh) | 2022-05-11 | 2025-12-02 | 株式会社前川制作所 | 削切装置及工件的削切方法 |
| WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
| CN115093397B (zh) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | 一种用于治疗肿瘤的化合物、合成方法及应用 |
| WO2024066984A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 三并环类衍生物、药物组合物以及应用 |
| WO2024140653A1 (zh) * | 2022-12-27 | 2024-07-04 | 南京圣和药业股份有限公司 | 选择性cdk12/13抑制剂及其应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57169465A (en) * | 1981-04-13 | 1982-10-19 | Showa Denko Kk | Pyrazole derivative, its preparation and herbicide |
| AU4166400A (en) | 1999-02-11 | 2000-08-29 | Cor Therapeutics, Inc. | Alkenyl and alkynyl compounds as inhibitors of factor xa |
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| KR100423899B1 (ko) | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
| EE05405B1 (et) * | 2000-08-10 | 2011-04-15 | Pharmacia Italia S.P.A. | Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid |
| JP2004517840A (ja) * | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| JP4553899B2 (ja) | 2003-08-21 | 2010-09-29 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| JP5507049B2 (ja) | 2004-12-30 | 2014-05-28 | アステックス、セラピューティックス、リミテッド | 医薬品 |
| JP2008526723A (ja) * | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| JP2008528469A (ja) | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
| GT200600457A (es) | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
| EP2089394B1 (en) | 2006-10-11 | 2011-06-29 | Nerviano Medical Sciences S.r.l. | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| WO2010002472A1 (en) * | 2008-07-02 | 2010-01-07 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| ATE544063T1 (de) | 2008-07-17 | 2012-02-15 | Koninkl Philips Electronics Nv | Nanoporenvorrichtung und verfahren zur nukleinsäureanalyse |
| US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
| FR2943058B1 (fr) | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| EP2241619A1 (en) * | 2009-04-17 | 2010-10-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Development of fluorescently P-loop labeled kinases for screening of inhibitors |
| JP6106685B2 (ja) * | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| US10112927B2 (en) * | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2014201073A1 (en) | 2013-06-13 | 2014-12-18 | Bristol-Myers Squibb Company | Macrocyclic factor viia inhibitors |
| RU2016111675A (ru) | 2013-08-30 | 2017-10-04 | Эмбит Байосайенсиз Корпорейшн | Соединения биарилацетамида и способы их применения |
| CA2926207C (en) | 2013-10-21 | 2022-06-21 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| AU2015240518A1 (en) | 2014-04-05 | 2016-10-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| FR3025075A1 (fr) * | 2014-08-28 | 2016-03-04 | Oreal | Nouveau dispositif de soin et/ou maquillage comprenant une composition d’architecture gel/gel |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3302448B1 (en) * | 2015-06-04 | 2023-10-25 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
-
2016
- 2016-06-03 EP EP16802673.0A patent/EP3302448B1/en active Active
- 2016-06-03 CN CN202111184551.4A patent/CN113773257A/zh active Pending
- 2016-06-03 WO PCT/IB2016/053267 patent/WO2016193939A1/en not_active Ceased
- 2016-06-03 KR KR1020187000333A patent/KR102691467B1/ko active Active
- 2016-06-03 US US15/579,246 patent/US10689347B2/en active Active
- 2016-06-03 MY MYPI2021007215A patent/MY198769A/en unknown
- 2016-06-03 CU CU2017000154A patent/CU24496B1/es unknown
- 2016-06-03 LT LTEPPCT/IB2016/053267T patent/LT3302448T/lt unknown
- 2016-06-03 CA CA2987552A patent/CA2987552A1/en active Pending
- 2016-06-03 MX MX2017015521A patent/MX375639B/es active IP Right Grant
- 2016-06-03 EA EA201890001A patent/EA037236B1/ru unknown
- 2016-06-03 JP JP2017561810A patent/JP6750806B2/ja active Active
- 2016-06-03 DK DK16802673.0T patent/DK3302448T3/da active
- 2016-06-03 CN CN201680045348.XA patent/CN108024970B/zh active Active
- 2016-06-03 PH PH1/2017/502179A patent/PH12017502179B1/en unknown
- 2016-06-03 MY MYPI2017001787A patent/MY190459A/en unknown
- 2016-06-03 SI SI201631797T patent/SI3302448T1/sl unknown
- 2016-06-03 FI FIEP16802673.0T patent/FI3302448T3/fi active
- 2016-06-03 AU AU2016272908A patent/AU2016272908B2/en active Active
- 2016-06-03 HR HRP20240101TT patent/HRP20240101T1/hr unknown
- 2016-06-03 EP EP23203356.3A patent/EP4342540A3/en not_active Withdrawn
-
2017
- 2017-11-28 IL IL255960A patent/IL255960B/en unknown
- 2017-12-01 MX MX2020010484A patent/MX2020010484A/es unknown
-
2018
- 2018-01-03 ZA ZA2018/00022A patent/ZA201800022B/en unknown
-
2020
- 2020-05-06 US US16/867,761 patent/US11174232B2/en active Active
- 2020-08-03 JP JP2020131775A patent/JP7033764B2/ja not_active Expired - Fee Related
-
2021
- 2021-08-04 AU AU2021212016A patent/AU2021212016B2/en active Active
- 2021-09-14 IL IL286428A patent/IL286428A/en unknown
- 2021-10-07 US US17/496,452 patent/US12331023B2/en active Active
-
2022
- 2022-02-18 JP JP2022024039A patent/JP7482918B2/ja active Active
-
2023
- 2023-06-06 AU AU2023203524A patent/AU2023203524A1/en not_active Abandoned